New clinical trial offers hope for patients with advanced “dry” age-related macular degeneration

https://www.news-medical.net/news/20251217/New-clinical-trial-offers-hope-for-patients-with-advanced-e2809cdrye2809d-age-related-macular-degeneration.aspx

Sitting harms blood vessel function, but cocoa flavanols can stop it

https://www.news-medical.net/news/20251217/Sitting-harms-blood-vessel-function-but-cocoa-flavanols-can-stop-it.aspx A simple cocoa-based intervention taken just before long periods of sitting can help preserve blood vessel function in both the arms and the legs. This highlights a practical nutritional strategy to counter the hidden cardiovascular risks of modern sedentary life.

Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology ++ +...

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-8KGpoy87VI4ht9FYkINihi8PvuSRwkHWCVB3G75Ms9LnxUXLu7fG0wtuA1WLiBXtkOnWj4rImaLvzaCaNVLgE7NWsZ8Q&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00295-9/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--uO0YWGE69YvRfurJq8h-auWMBUoABX5SKuwQOWl8klgI_CeP54dTefS36F5f1aY3yQkpMkagDkis00W9HgNjRSDAvkA&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol12no12/PIIS2352-3026(25)X0012-0

Advancing Treatment for HER2-Positive Advanced Breast Cancer: Expert Analysis of the Latest Developments Authors: Judy King, MRCP, PhD; Peter Fasching, MD

https://www.medscape.org/viewarticle/1002765?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-1002765-cta

Navigating the Storm of Heavily Pretreated Multiple Myeloma: Calming the Waters With Bispecific Antibodies Authors: Hermann C. Einsele, MD, PhD; Xavier Leleu, MD, PhD; Naresh Bumma, MD

https://www.medscape.org/viewarticle/1002692?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002692-cta

Patients’ Insights Illuminated: A Rapid-Fire Dive Into CLL and MCL Authors: Lorna Warwick; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD; Nicole Lamanna, MD; David Ball; Vivienne Ball

https://www.medscape.org/viewarticle/1002737?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002737-cta

Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer: Translating Science Into Clinical Practice Authors: Rahul Gosain, MD, MBA; Rohit Gosain, MD; David S. Hong, MD; Theodore W. Laetsch, MD; Jarushka Naidoo, MB, BCH, MHS

https://www.medscape.org/viewarticle/1002679?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002679-cta

Evidence and responsibility of artificial intelligence use in mental health care The Lancet Digital Health ++... ++

https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00141-4/fulltext?dgcid=raven_jbs_etoc_email Nov 2025 Volume 7Number 11 https://www.thelancet.com/journals/landig/issue/vol7no11/PIIS2589-7500(25)X0011-X Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00096-2/fulltext?dgcid=raven_jbs_etoc_feature_landig Artificial intelligence imaging decision support for acute stroke treatment in England: a prospective observational study https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00109-8/fulltext?dgcid=raven_jbs_etoc_feature_landig

A day in the life: reconciling grief and gratitude 17 December 2025

https://rarerevolutionmagazine.com/a-day-in-the-life-reconciling-grief-and-gratitude/ I wake before the sun most days—not because I want to, but because my body decides it’s time. Pain pulls me out of sleep before my mind has even caught up. I stretch carefully, the way you’d handle something fragile and cracked, always wondering if today will be the day a piece of me finally breaks.

Aducanumab: advancing Alzheimer’s treatment through regulation of excessive β-amyloid accumulation Clotilde Nsimire Katana Kachungunu [1] , Subhash Namdeo Mashal [1] , Priyadarshi Soumyaranjan Sahu* [1]

https://www.academia.edu/academia-immunity-and-disease/1/1/10.20935/AcadImmunoDis8055 Abstract Objective: Several drugs have been studied in past decades, with the main purpose of primarily being used for the symptomatic relief of Alzheimer’s Disease (AD). As of today, there are hundreds of ongoing studies to find a pharmacological treatment that will not only lessen the neurological symptoms of AD but will also slow down the progression or find a definite cure for the disease. We hypothesized that the emerging treatments for AD, such as Aducanumab, should primarily target the excessive brain accumulation of either β-amyloid peptides or tau proteins, thus delay the progression of illness when compared to the standard pharmacological treatment. The present systematic review explored and addressed Aducanumab therapy as an emerging treatment to cure, prevent, or slow down AD progression. Methods: A comprehensive literature search was conducted on PubMed using predefined search terms; the identified studies were then screened. Finally, 47 of the 210 articles were included for data extraction and analysis. Results: This study analyzed the validity and efficacy of Aducanumab. Aducanumab is a pharmacotherapy that targets excessive β-amyloid peptides in the brain; however, it does not have any role in reducing aggregated hyperphosphorylated tau proteins. Aducanumab has been analyzed and juxtaposed with the standard treatment, acetylcholinesterase inhibitors. Aducanumab is an effective pharmacotherapy that lowers β-amyloid peptides in the brain, and therefore, it helps treat AD. The side effects of Aducanumab are not deemed significant enough to justify FDA disapproval, and they can easily be monitored and prevented. Conclusions: Aducanumab has been proven to be a very effective and promising pharmacotherapy in treating AD. It is also the first disease-modifying pharmacotherapy for AD, and compared to the standard treatment, it is preferable in all aspects for slowing down or stopping the progression of AD.

Enhancing Impactful Patient-Centered Care for NMSC Through Meaningful Connections Authors: Dirk Schadendorf, MD; Emily Ruiz, MD, MPH

https://www.medscape.org/viewarticle/1002953?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002953-cta

Applying Guideline-Directed Systemic Therapy for Advanced Bladder Cancer Dr Jose Tapia discusses guideline recommendations for systemic treatment in bladder cancer, and assesses therapeutic developments that will further shape guidance and improve outcomes Dr Jose Tapia

Applying Guideline-Directed Systemic Therapy for Advanced Bladder Cancer Dr Jose Tapia discusses guideline recommendations for systemic treatment in bladder cancer, and assesses therapeutic developments that will further shape guidance and improve outcomes Dr Jose Tapia https://reference.medscape.com/cc1/p10/applying-guideline-directed-systemic-therapy-advanced-2025a1000lvm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Top Tips: Metastatic Breast Cancer Dr Fharat Raja provides 10 top tips for oncologists on metastatic breast cancer, encompassing the latest UK, European, and US guidance Dr Fharat Raja

Top Tips: Metastatic Breast Cancer Dr Fharat Raja provides 10 top tips for oncologists on metastatic breast cancer, encompassing the latest UK, European, and US guidance Dr Fharat Raja https://reference.medscape.com/cc1/p10/top-tips-metastatic-breast-cancer-2025a1000dc0?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Metastatic Malignant Disease of Unknown Primary Origin in Adults: Diagnosis and Management Source: National Institute for Health and Care Excellence

Metastatic Malignant Disease of Unknown Primary Origin in Adults: Diagnosis and Management Source: National Institute for Health and Care Excellence Cancer of Unknown Primary (NICE) •Initial diagnostic steps https://reference.medscape.com/cc2/p10/metastatic-malignant-disease-unknown-primary-origin-adults-2023a1000fgz?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611#1 •When to use PET–CT scans https://reference.medscape.com/cc2/p10/metastatic-malignant-disease-unknown-primary-origin-adults-2023a1000fgz?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611#1

Bladder Cancer (ESMO) Source: European Society for Medical Oncology; Medically Reviewed by Professor Noel Clarke

Bladder Cancer (ESMO) Bladder Cancer Source: European Society for Medical Oncology; Medically Reviewed by Professor Noel Clarke •Imaging and cytoscopy https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Augmented visualization for TURBT https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Neoadjuvant chemotherapy for MIBC https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Breast Cancer Germline Testing (ASCO) Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja

Breast Cancer Germline Testing (ASCO) Germline Testing in Breast Cancer Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja In 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published a guideline on germline testing in breast cancer. This Medscape guideline summary covers BRCA1/2 testing for newly diagnosed patients, those with recurrent disease or second primaries, and those with personal history but no active disease, as well as the value of testing for other predisposition genes and genetic counselling. Please refer to the full ASCO–SSO guideline for all recommendations, rationale, and background information. •When to offer BRCA1/2 testing https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Testing for stage I–IV disease https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Recurrent cancer and PARP inhibitors https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Palliative Care (ASCO) Source: American Society of Clinical Oncology; Medically Reviewed by Professor Graham Jackson

Palliative Care (ASCO) Palliative Care Integration in Cancer Care Source: American Society of Clinical Oncology; Medically Reviewed by Professor Graham Jackson In 2024, the American Society of Clinical Oncology (ASCO) published an updated guideline on palliative care for patients with cancer. This Medscape guideline summary for oncologists provides recommendations regarding optimal provision of palliative care services for patients with cancer and their caregivers, updating previous ASCO guidance from 2012 and 2016. The update aims to equip oncology professionals with current recommendations while evaluating the continued validity of previous guidance, and includes new discussions on integrating palliative care for patients with haematological malignancies and those enrolled in phase I clinical trials, as well as addressing health equity in oncology palliative care. •When to introduce palliative care https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Referral for poor-prognosis cancers https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Supporting caregiver needs https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Immunotherapy for Multiple Myeloma (IMWG) Source: International Myeloma Working Group Immunotherapy Committee

Immunotherapy for Multiple Myeloma (IMWG) Sequencing Immunotherapy for Multiple Myeloma Source: International Myeloma Working Group Immunotherapy Committee In 2025, the International Myeloma Working Group Immunotherapy Committee published a set of nine consensus recommendations for the optimal sequential use of immunotherapy agents in the treatment of multiple myeloma. These recommendations were developed by a panel of experts based on the current available evidence. •TCRT or CAR-T cell therapy https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •TCE for rapid progression https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Progressive MM alternatives https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Cancer Immunotherapy: Squamous Cell Carcinoma of the Head and Neck Source: Society for Immunotherapy of Cancer

Head and Neck SCC (SITC) Cancer Immunotherapy: Squamous Cell Carcinoma of the Head and Neck Source: Society for Immunotherapy of Cancer •Biomarker testing https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Immunotherapy strategies https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Evaluating treatment responses https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Testicular Cancer (EAU) Source: European Association of Urology

Testicular Cancer (EAU) Testicular Cancer Source: European Association of Urology •Tumor classification https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •CS I seminoma: surveillance vs carboplatin https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Testis-sparing surgery criterias https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Fructans and ATIs impact digestive health in beer

https://www.news-medical.net/news/20251216/Fructans-and-ATIs-impact-digestive-health-in-beer.aspx

A multi-gene mouse model reveals new mechanisms of Hirschsprung disease

https://www.news-medical.net/news/20251216/A-multi-gene-mouse-model-reveals-new-mechanisms-of-Hirschsprung-disease.aspx

How Artificial Food Coloring Affects Children's Behavior and Health

https://www.news-medical.net/health/How-Artificial-Food-Coloring-Affects-Children-Behavior-and-Health.aspx Synthetic food dyes are widely used in packaged foods and can disproportionately affect children due to higher relative intake and developmental vulnerability. Evidence from clinical trials, animal studies, and regulatory reviews links certain dyes to behavioral changes, allergic reactions, and emerging concerns involving the gut–brain axis.

How Mycotoxin Contamination in Food Impacts Human Health

https://www.news-medical.net/health/How-Mycotoxin-Contamination-in-Food-Impacts-Human-Health.aspx Mycotoxins are toxic fungal metabolites that contaminate staple foods across the supply chain, posing widespread risks to human health even at low exposure levels. This article explains how mycotoxins enter food, the diseases they cause, who is most vulnerable, and how contamination can be detected and prevented.

Improving mCRPC Outcomes Using Radiopharmaceuticals: Evidence to Implementation Authors: Rana R. McKay, MD, FASCO; Matthew R. Cooperberg, MD, MPH; Sean M. McBride, MD, MPH, MS

https://www.medscape.org/viewarticle/1003039_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251215-1003039_ES_HONC

FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive?utm_medium=email&utm_source=govdelivery

Managing Progression on Frontline Immunotherapy: A Multidisciplinary Case Approach In Metastatic Melanoma Authors: Gino K. In, MD, MPH; Sunandana Chandra, MD, MS; Robert J. Lewandowski, MD; Ali Rastegarpour, MD

https://www.medscape.org/viewarticle/1002675?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-1002675-cta

Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions Authors: Judith Eelloo, RGN, RSCN, MPhil; Darren Hargrave, MD; Zhichao Wang, MD, MPH; Kaleb Yohay, MD

https://www.medscape.org/viewarticle/optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5-cta

FDA Approves Drug for Type of Abnormally Fast Heart Rhythm

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218571s000lbl.pdf?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration (FDA) has approved Cardamyst (etripamil) nasal spray to treat episodes of paroxysmal supraventricular tachycardia (PSVT), a condition where the heart beats abnormally fast. Disease or Condition People with paroxysmal supraventricular tachycardia (PSVT) have episodes in which their heart beats very fast, over 100 beats per minute. Symptoms can include heart palpitations, chest discomfort, shortness of breath, dizziness or lightheadedness, and fainting. PSVT occurs when a short circuit rhythm develops in the heart’s upper chamber. Symptoms persist until the normal heart rhythm is restored. Rarely, PSVT can damage the heart if it occurs often, leading to dilated cardiomyopathy. Data Supporting Cardamyst The safety and efficacy of Cardamyst were evaluated in the RAPID study (NCT #03464019), a double-blind, placebo-controlled phase 3 study in which 692 patients were randomly assigned to receive Cardamyst 70 mg or a placebo. Patients with an episode of perceived PSVT self-administered one dose of the drug and self-administered a second dose if symptoms persisted 10 minutes after the first dose. The primary endpoint was time it took for the abnormal heart rhythm to return to normal and stay normal for at least 30 seconds. Results showed that 64% and 31% of patients receiving Cardamyst and placebo, respectively, returned to normal heart rhythms within 30 minutes. The median (midpoint) time it took to return to normal was approximately 17 minutes for patients taking Cardamyst compared with 54 minutes for patients taking the placebo. Safety Information The most common side effects with Cardamyst are nasal discomfort, nasal congestion, runny nose, throat irritation, and nose bleeds. Patients with a hypersensitivity to Cardamyst or its components, heart failure, or certain other pre-conditions should not take Cardamyst. The medication may cause dizziness or fainting, so people should administer Cardamyst in a sitting position.

Targeting viral entry to expand antiviral drug discovery strategies

Targeting viral entry to expand antiviral drug discovery strategies New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development. https://www.drugdiscoverynews.com/targeting-viral-entry-to-expand-antiviral-drug-discovery-strategies-16902

Articles on Neurology // Calculators

https://emedicine.medscape.com/neurology?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Calculators https://reference.medscape.com/guide/medical-calculators?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

Top Tips: Care for Women with Fatigue and/or Chronic Pain

Top Tips: Care for Women with Fatigue and/or Chronic Pain Dr Louise Newson, Professor Deepak Ravindran, Dr Sarah Glynne, and Dr Ellen Fallows offer 10 top tips for primary care practitioners on improving care for women with fatigue and/or pain Dr Louise Newson, Prof Deepak Ravindran, Dr Sarah Glynne, Dr Ellen Fallows https://reference.medscape.com/cc1/p10/top-tips-care-women-fatigue-and-or-chronic-pain-2024a10009vj?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Read This Article to Learn More About: fatigue, chronic pain, and the conditions commonly associated with these symptoms ways to improve the assessment and management of these symptoms in primary care potential benefits of lifestyle changes and hormone-replacement therapy including testosterone for women experiencing these symptoms. Implementation actions for integrated care systems can be found at the end of this article.

Adopt an Anticipatory and Multifaceted Approach to Dementia in Primary Care

Adopt an Anticipatory and Multifaceted Approach to Dementia in Primary Care Dr Sigi Joseph reviews the latest SIGN guidance on dementia, highlighting the key recommendations for implementation in general practice Dr Sigi Joseph https://reference.medscape.com/cc1/p10/adopt-anticipatory-and-multifaceted-approach-dementia-2024a1000iza?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Read This Article to Learn More About: the diagnosis and classification of dementia anticipatory care planning and early, postdiagnostic support for people with dementia and their carers the role of general practice in ongoing support, medications management, treatment of comorbidities, and end-of-life care.

INSOMNIA (Riemann et al.)

INSOMNIA (Riemann et al.) Diagnosis and Treatment of Insomnia Source: Riemann D, Espie C, Altena E et al This Medscape summary covers recommendations from the updated European Insomnia Guideline on the diagnosis and management of insomnia, and includes a useful therapeutic algorithm as a guide for treatment. •ICSD-3 and ICD-11 criteria https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Drug treatment classes https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Nonpharmacological treatments https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

TRIGEMINAL NEURALGIA (Lambru et al.)

TRIGEMINAL NEURALGIA (Lambru et al.) Trigeminal Neuralgia: A Practical Guide Source: Lambru G, Zakrzewski J, and Matharu M This Medscape guideline summary of Trigeminal neuralgia: a practical guide covers the diagnosis, clinical features, investigations, differential diagnosis, and treatment of trigeminal neuralgia (TN). For information on pathophysiology, acute treatment for severe exacerbation, surgical treatments, and other considerations, refer to the full practical guide. •The 3 TN subgroups https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •The role of MRI in workup https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •First-line treatment options https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

LOW BACK PAIN (WHO)

LOW BACK PAIN (WHO) Non-Surgical Management of Chronic Primary Low Back Pain in Adults in Primary and Community Care Settings Source: World Health Organization This is a Medscape summary of the World Health Organization’s guidance on managing chronic primary low back pain (CPLBP) in adults. Recommendations included cover education and advice, physical and psychological interventions, and medicines. •Tailored exercise programs https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Short-term pain relief https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •When to prescribe NSAIDs https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

RESTLESS LEGS SYNDROME (AASM)

RESTLESS LEGS SYNDROME (AASM) Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder Source: American Academy of Sleep Medicine; Medically Reviewed by Dr Roger Henderson •Essential iron studies https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 In 2025, the American Academy of Sleep Medicine (AASM) published a guideline on the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD).[1] This Medscape overview for general practitioners examines the AASM recommendations on diagnosis, management, and follow up of RLS and PLMD, covering clinical presentation, investigations, and pharmacological and nonpharmacological treatment options, with reference to other sources of information on the topic. •First-line therapies https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •New treatment options https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

ACUTE MIGRAINE (IHS)

ACUTE MIGRAINE (IHS) •Initiating higher triptan doses Acute Pharmacological Treatment of Migraine Source: International Headache Society https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 This Medscape summary of International Headache Society guidance covers practical, international, evidence-based recommendations from the International Headache Society on the acute pharmacological management of migraine. Recommendations are categorised into two levels: optimal and essential. The optimal level is intended for settings where most drug treatments are available. The essential level is intended for underserved areas, where treatment options are limited or that can only count on the medications listed in the World Health Organization (WHO) model list of essential medicines (EML). •Combining triptans and NSAIDs https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Treatment of early vomiting https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

EARLY ALZHEIMER'S DISEASE (Porsteinsson et al.)

EARLY ALZHEIMER'S DISEASE (Porsteinsson et al.) •Recognizing AD pathology Diagnosis of Early Alzheimer’s Disease Source: Porsteinsson A, Isaacson R, Knox S et al https://reference.medscape.com/cc2/p10/diagnosis-early-alzheimers-disease-2025a10002dd?sso=true&uac=148436CN&ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&impID=7957108 This Medscape guideline summary covers the role of primary healthcare professionals (HCPs) in identifying and recognising Alzheimer’s disease (AD), and includes methods for assessing for potential AD as well as differential diagnoses. For information on specialist care in terms of assessment, diagnosis, and treatment, refer to the full guideline. •Screening for reversible causes https://reference.medscape.com/cc2/p10/diagnosis-early-alzheimers-disease-2025a10002dd?sso=true&uac=148436CN&ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&impID=7957108 •Assessing early symptoms https://reference.medscape.com/cc2/p10/diagnosis-early-alzheimers-disease-2025a10002dd?sso=true&uac=148436CN&ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&impID=7957108

STROKE PREVENTION (AHA/ASA)

STROKE PREVENTION (AHA/ASA) •ASCVD risk in adults https://reference.medscape.com/cc2/p10/guideline-essentials-2024-aha-asa-recommendations-primary-2025a1000cor?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Primary Prevention of Stroke American Heart Association, American Stroke Association; Medically Reviewed by Dr Roger Henderson In 2024, the American Heart Association (AHA) and the American Stroke Association (ASA) published an updated guideline on the primary prevention of stroke, replacing the 2014 version.[1] The guideline provides evidence-based recommendations on stroke-prevention strategies for individuals with or at risk of developing cerebrovascular disease. The recommendations align with the AHA's Life's Essential 8 framework for optimising cardiovascular and brain health and include new sex-specific recommendations for screening and prevention that were not in the 2014 guideline. •Life's Essential 8 https://reference.medscape.com/cc2/p10/guideline-essentials-2024-aha-asa-recommendations-primary-2025a1000cor?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108#13 •GLP-1 RA considerations https://reference.medscape.com/cc2/p10/guideline-essentials-2024-aha-asa-recommendations-primary-2025a1000cor?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108#13

Academia Drug Development and Pharmacotherapy: a new scientific translational journal focused on personalized therapy Federico Pea* [1,2]

Academia.edu is launching a new scientific journal in the field of drug development and pharmacotherapy. This will be a translational journal focused on all the different aspects which, from bench to bedside, may enable maximizing the likelihood of providing more effective and safe pharmacotherapy in the era of precision medicine. Modern pharmacotherapy is increasingly based on well-defined molecular targets, and this may clearly improve effectiveness, especially in some fields such as oncology. However, there is an urgent need to personalize therapy to each individual patient, escaping from the false contention that “one size may fit all” and moving toward tailored therapies based on predictive models. This has been well-defined in the last twenty years or so, especially in the field of antibiotic therapy, in which both underlying diseases and pathophysiology have been shown to deeply alter the pharmacokinetic–pharmacodynamic behavior of drugs with the consequent need of individualized dosing regimens. Indeed, the same is also expected to occur in other therapeutic areas, and just to mention one among many, recent studies suggest that a paradigm shift to personalized dosing regimens might be applied even to the major topic of therapeutic monoclonal antibodies. https://www.academia.edu/academia-drug-development-and-pharmacotherapy/1/1/10.20935/AcadDrug7906

What are the treatment options for Rheumatoid Arthritis (Medscape AI) +... +++++

https://www.medscape.com/ai-search?query=What%20are%20the%20treatment%20options%20for%20Rheumatoid%20Arthritis&&ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN&impID=7949649 Could SGLT2 Inhibitors Reduce Rheumatoid Arthritis Flares? https://www.medscape.com/viewarticle/could-sglt2-inhibitors-reduce-rheumatoid-arthritis-flares-2025a1000xvs?ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN&impID=7949649 Fiber, Bacteria Likely Influence Methotrexate Response in RA https://www.medscape.com/viewarticle/fiber-gut-bacteria-likely-influence-methotrexate-response-2025a1000xyt?ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN Do Patients With RA on ICIs Have a Higher Mortality Risk? https://www.medscape.com/viewarticle/do-patients-ra-immune-checkpoint-inhibitors-have-higher-2025a1000x5y?ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN&impID=7949649 Risk Score Validated to Predict Lung Disease in RA https://www.medscape.com/viewarticle/risk-score-validated-predict-lung-disease-rheumatoid-2025a1000x62?ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN&impID=7949649 Sleep Disorders Common in RA, Many Tied to Disease Activity https://www.medscape.com/viewarticle/sleep-disorders-common-ra-many-tied-disease-activity-2025a1000vue?ecd=mkm_ret_251215_mscpmrk-OUS_InFocus_etid7949649&uac=148436CN&impID=7949649

Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-1002936-cta

AI helps radiologists find breast cancers earlier and faster Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency.

https://www.drugdiscoverynews.com/ai-helps-radiologists-find-breast-cancers-earlier-and-faster-16830

Why we’re going back to the moon By Bioethics Observatory Published On: November 3rd, 2025

https://bioethicsobservatory.org/2025/11/why-were-going-back-to-the-moon/48159/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Stem cells and organoids: the revolution transforming biomedicine that demands bioethical reflection By Bioethics Observatory Published On: November 28th, 2025

https://bioethicsobservatory.org/2025/11/stem-cells-and-organoids-the-revolution-transforming-biomedicine-that-demands-bioethical-reflection/48221/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Social networks, digital screen exposure, and neurodevelopmental disorders By Bioethics Observatory Published On: December 3rd, 2025

https://bioethicsobservatory.org/2025/12/social-networks-digital-screen-exposure-and-neurodevelopmental-disorders/48247/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Abortion and health: Are there long-term consequences for women after an abortion? By Bioethics Observatory Published On: November 24th, 2025

https://bioethicsobservatory.org/2025/11/abortion-and-mental-health-are-there-long-term-consequences-for-women-after-an-abortion/48186/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

How does alcohol impair the liver’s ability to fully regenerate after injury (Medscape AI) +... ++++++ +...

Alcohol disrupts multiple cellular pathways that are critical for hepatocyte proliferation and functional recovery. The key mechanisms include metabolic toxicity, oxidative injury, immune‐mediated perpetuation of damage, and interference with hepatocyte maturation programs. https://www.medscape.com/ai-search?query=How%20does%20alcohol%20impair%20the%20liver%E2%80%99s%20ability%20to%20fully%20regenerate%20after%20injury&ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 NEWS & COMMENTARY The High Road to Avoid Alcohol https://www.medscape.com/viewarticle/high-road-avoid-alcohol-2025a1000w07?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 3+ Drinks Daily Tied to Worse Intracerebral Hemorrhage https://www.medscape.com/viewarticle/three-or-more-drinks-day-tied-earlier-more-severe-2025a1000v6w?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 When Alcohol and COPD Collide, Lungs Suffer More https://www.medscape.com/viewarticle/when-alcohol-and-copd-collide-lungs-suffer-more-2025a1000wxf?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 Readiness-to-Change Scores Predict Alcohol Treatment Uptake https://www.medscape.com/viewarticle/higher-readiness-change-scores-emergency-department-patients-2025a1000xa2?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 Alcohol and Wellness: What's at Stake https://reference.medscape.com/slideshow/complications-alcoholism-6000415?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 Alcohol-Cancer Link Unknown to Many Adults https://www.medscape.com/viewarticle/us-adults-show-low-awareness-alcohol-cancer-link-2025a1000tpr?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171 COMING IN ‘DRY JANUARY’ In a special series of Impact Factor videos, Dr. F. Perry Wilson will explore the multifaceted effects of alcohol on the human body. https://www.medscape.com/index/list_12471_0?ecd=mkm_ret_251210_mscpmrk_pcp_alcohol_etid7940171&uac=148436CN&impID=7940171

Be the First to Know about the Traveler’s Guide To Outsmarting AI: and more! +++++

Bots Vs. Bucks: The Traveler’s Guide To Outsmarting AI Data shows 77% of companies are either using A.I. and the travel industry is no exception. From airlines to hotels, bots are setting prices and personalizing offers. So, how can you outsmart artificial intelligence and still get the best deal? Continue » https://www.ivanhoe.com/smart-living/bots-vs-bucks-the-travelers-guide-to-outsmarting-ai/ The Workplace Showdown: When Quitting And Firing Go Quiet The silent treatment isn’t just for relationships; it’s happening at work too. Remember quiet quitting, when employees stopped going above and beyond? Now quiet firing is on the rise. See how both sides subtly edge workers out without ever saying, “You’re fired.”. Continue » https://www.ivanhoe.com/?p=36417&preview=1&_ppp=6d90f046b9 Cool It! The Mistakes You’re Making After The Gym You stretch, you sweat, you push your limits — and finishing a workout feels great. But what happens next matters even more. See what not to grab after the gym. It can help your health in more ways than one. Continue » https://www.ivanhoe.com/?p=36420&preview=1&_ppp=351da5eb3c Parent Traps To Avoid In 2026 A New York Times poll found more than 75% of parents admit to “snowplowing” obstacles out of their child’s path. As the new year approaches, find out the new parenting traps and find out if it may be time to re-examine your parenting style. Continue » https://www.ivanhoe.com/?p=36423&preview=1&_ppp=adc9f87222 The AI Advisor: Friend Or Financial Risk? A new survey finds that nearly half of Americans feel more comfortable using A.I. for financial decisions than they did just a year ago. But can you really trust a chatbot with your money? https://www.ivanhoe.com/?p=36426&preview=1&_ppp=f35204b3cb

How High-Heat Cooking Creates Carcinogens in Food +++

How High-Heat Cooking Creates Carcinogens in Food https://www.news-medical.net/health/How-High-Heat-Cooking-Creates-Carcinogens-in-Food.aspx High-temperature cooking creates harmful carcinogens such as HCAs, PAHs, acrylamide, and nitrosamines through reactions involving proteins, sugars, fats, and smoke. Understanding how these compounds form enables safer cooking methods that reduce cancer-related risks without compromising food quality. New research reveals underestimation of food insecurity https://www.news-medical.net/news/20251213/New-research-reveals-underestimation-of-food-insecurity.aspx Optimizing potassium channel assays for high-throughput applications https://www.news-medical.net/health/Optimizing-potassium-channel-assays-for-high-throughput-applications.aspx This article and associated images are based on a poster originally authored by Sivakumar, M, Smith, E, Shumate, J, Scampavia, L, Spicer, T, Hernandez, D and Peters, C and presented at ELRIG Drug Discovery 2025 in affiliation with BMG LABTECH and UF Scripps Institute.

What is IMAGe Syndrome? Causes, Diagnosis, Genetics and Treatment

https://www.news-medical.net/health/What-is-IMAGe-Syndrome-Causes-Diagnosis-Genetics-and-Treatment.aspx IMAGe syndrome is a rare, maternally inherited CDKN1C-related disorder characterized by prenatal growth restriction, adrenal hypoplasia, skeletal anomalies, and genital abnormalities. Early diagnosis and lifelong adrenal management significantly improve outcomes and guide accurate genetic counseling.

Digital pathology and the PathoVerse: A conversation with Dr. Singh

https://www.news-medical.net/news/20251212/Digital-pathology-and-the-PathoVerse-A-conversation-with-Dr-Singh.aspx In this interview, industry expert Dr. Raj Singh discusses the PathoVerse, a pioneering global digital ecosystem designed to transform pathology through connectivity, AI integration, and collaborative innovation across research and clinical practice.

The Muscle Help Foundation and its patron, Lorraine Kelly, call on supporters to donate in the UK’s biggest public fundraiser, the ‘Big Give Christmas Challenge’ 8 December 2025

https://rarerevolutionmagazine.com/the-muscle-help-foundation-and-its-patron-lorraine-kelly-call-on-supporters-to-donate-in-the-uks-biggest-public-fundraiser-the-big-give-christmas-challenge/ Funds raised will help this small multi award-winning charity continue its vital work supporting families living with muscular dystrophy

Patient organisation Cure HSPB8 adopts new name: Cure MFM13 8 December 2025

https://rarerevolutionmagazine.com/patient-organisation-cure-hspb8-adopts-new-name-cure-mfm13/ The condition at the centre of our work has long been referred to by several different names, including HSPB8 myopathy and distal myopathy with rimmed vacuoles. This variety of terminology has often made it challenging for patients, families, and researchers to access clear and reliable information.

From silence to support: the journey of CS ECHO and Cowden syndrome 10 December 2025

https://rarerevolutionmagazine.com/from-silence-to-support-the-journey-of-cs-echo-and-cowden-syndrome/ Salima Qribis talks of her experience navigating an “invisible” rare disease and her mission to make the invisible, visible

Without FDA flexibility for rare diseases our daughter’s future is at risk 8 December 2025

https://rarerevolutionmagazine.com/without-fda-flexibility-for-rare-diseases-our-daughters-future-is-at-risk/ Meagan DeRaps shares her family's fight for their daughter, who has a rare disease (PDCD). A clinical trial medication has provided a vital lifeline for over three years, but the FDA's recent non-approval puts her future at risk. They urge the FDA for regulatory flexibility now.

A tough year 10 December 2025

https://rarerevolutionmagazine.com/a-tough-year/ Nicola Redfern is back with her final Industry Insights for 2025. In a year that was tough for biotech and pharma, with policy uncertainty and negotiations slowing access to rare disease innovations, 2026 offers hope with MHRA-NICE collaboration, new rare disease models, and higher NICE thresholds.

2025 Orphan Drugs: PDUFA Dates and FDA Approvals ++++ ++++

FDA NEWS 2025 Orphan Drugs: PDUFA Dates and FDA Approvals https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/ Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. FDA Approves Hyrnua for HER2-Positive Non-Small Cell Lung Cancer https://checkrare.com/fda-approves-hyrnua-for-her2-positive-non-small-cell-lung-cancer/ The U.S. FDA has approved Hyrnua (sevabertinib) for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain activating mutations. Selumetinib to Treat Patients With Neurofibromatosis Type 1 https://checkrare.com/fda-approves-selumetinib-to-treat-patients-with-neurofibromatosis-type-1/ The U.S. FDA has approved Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Updates to Prescribing Information for Elevidys in Treatment of Duchenne Muscular Dystrophy https://checkrare.com/updates-to-prescribing-information-for-elevidys-in-treatment-of-duchenne-muscular-dystrophy/ The U.S. FDA has updated the prescribing information for Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy (DMD). Approval of Treatment for Patients With Familial Chylomicronemia Syndrome (FCS) https://checkrare.com/approval-of-treatment-for-patients-with-familial-chylomicronemia-syndrome-fcs/ The U.S. FDA has approved Redemplo (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome (FCS). Ziftomenib for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia https://checkrare.com/fda-approves-ziftomenib-for-relapsed-refractory-npm1-mutated-acute-myeloid-leukemia/ The U.S. FDA has approved Komzifti (ziftomenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible NPM1 mutation. Darzalex Faspro for Patients With High-Risk Smoldering Multiple Myeloma https://checkrare.com/fda-approves-darzalex-faspro-for-patients-with-high-risk-smoldering-multiple-myeloma/ The U.S. FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). FDA Approves First Treatment for Thymidine Kinase 2 Deficiency https://checkrare.com/fda-approves-first-treatment-for-thymidine-kinase-2-deficiency/ The U.S. FDA has approved Kygevvi for the treatment of adults and pediatric patients, with an age of symptom onset on or before 12 years, with thymidine kinase 2 deficiency (TK2d).

CLINICAL PERSPECTIVES ++++ ++++ ++++

CLINICAL PERSPECTIVES ORIGIN 3 Clinical Trial Evaluating Atacicept in Adults With IgA Nephropathy https://checkrare.com/origin-3-clinical-trial-evaluating-atacicept-in-adults-with-iga-nephropathy/ Richard Lafayette, MD, Professor of Medicine at Stanford University, discusses the ORIGIN clinical trial evaluating atacicept in adults with IgA nephropathy (IgAN). The Use of Nipocalimab in Adolescent Patients With Generalized Myasthenia Gravis https://checkrare.com/the-use-of-nipocalimab-in-adolescent-patients-with-generalized-myasthenia-gravis/ Jonathan Strober, MD, pediatric neurologist and neuromuscular specialist at the University of California at San Francisco, discusses the use of nipocalimab in adolescent patients with generalized myasthenia gravis (gMG). Positive Topline Results from the CALIBRATE Trial of Encaleret in Patients With Autosomal Dominant Hypocalcemia Type 1 https://checkrare.com/positive-topline-results-from-the-calibrate-trial-of-encaleret-in-patients-with-autosomal-dominant-hypocalcemia-type-1/ Michael A. Levine, MD, ML, Children’s Hospital of Philadelphia, discusses positive topline results from the CALIBRATE trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). EPIC Clinical Trial Design: Evaluating Nipocalimab Versus Efgartigimod in Patients With Myasthenia Gravis https://checkrare.com/epic-clinical-trial-design-evaluating-nipocalimab-versus-efgartigimod-in-patients-with-myasthenia-gravis/ Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with generalized myasthenia gravis (gMG). Efficacy of Nipocalimab in Generalized and Ocular gMG: Long-Term Outcomes and Phase 3 VIVACITY-MG3 Findings https://checkrare.com/efficacy-of-nipocalimab-in-generalized-and-ocular-gmg-long-term-outcomes-and-phase-3-vivacity-mg3-findings/ Sindhu Ramchandren, MD, Executive Medical Director of Neuroscience at Johnson & Johnson, discusses long-term efficacy of nipocalimab in patients with generalized myasthenia gravis (gMG). Ongoing Phase 3 Study of Paltusotine in Carcinoid Syndrome Due to Neuroendocrine Tumors https://checkrare.com/ongoing-phase-3-study-of-paltusotine-in-carcinoid-syndrome-due-to-neuroendocrine-tumors/ Aman Chauhan, MD, Oncologist at the University of Miami, discusses details of a phase 3 study testing paltusotine in patients with carcinoid syndrome due to neuroendocrine tumors (NETs). The Shift to Precision Medicine in Myasthenia Gravis https://checkrare.com/the-shift-to-precision-medicine-in-myasthenia-gravis/ Alexandra C. Bayer Wildberger, PhD, Post-Doctoral Associate at Yale School of Medicine, discusses the shift to precision medicine in myasthenia gravis (MG). Long-Term Data From the AQUARIUS Study of Avacopan in Patients With GPA and MPA https://checkrare.com/long-term-data-from-the-aquarius-study-of-avacopan-in-patients-with-gpa-and-mpa/ Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Data on the RAISE Clinical Trial Program of Zilucoplan for the Treatment of Myasthenia Gravis https://checkrare.com/data-on-the-raise-clinical-trial-program-of-zilucoplan-for-the-treatment-of-myasthenia-gravis/ Michael Weiss, MD, Neurologist at the University of Washington, discusses data on the RAISE and RAISE-XT clinical trials of zilucoplan for the treatment of generalized myasthenia gravis (gMG). New Data on Vyvgart for Patients With AChR-Ab Seronegative Myasthenia Gravis https://checkrare.com/new-data-on-vygart-for-patients-with-achr-ab-seronegative-myasthenia-gravis/ James Howard, Jr., MD, Professor of Neurology at the University of North Carolina, discusses new data on the safety and efficacy of Vyvgart (efgartigimod alfa) for patients with AChR-Ab seronegative generalized myasthenia gravis (gMG). A Patient’s Diagnostic Journey With Systemic Mastocytosis https://checkrare.com/a-patients-diagnostic-journey-with-systemic-mastocytosis/ Joan Smith, patient with systemic mastocytosis, discusses her diagnostic journey with systemic mastocytosis (SM). Results From the DeFi Clinical Trial of Nirogacestat in Patients With Desmoid Tumors https://checkrare.com/results-from-the-defi-clinical-trial-of-nirogacestat-in-patients-with-desmoid-tumors/ Bernd Kasper, MD, PhD, University of Heidelberg Cancer Center, discusses results from the DeFi clinical trial of nirogacestat in patients with desmoid tumors.

Updates in IPF Chronic Cough From CHEST 2025 ++++ ++++ ++++

FEATURED ARTICLES Updates in IPF Chronic Cough From CHEST 2025 https://checkrare.com/updates-in-ipf-chronic-cough-from-chest-2025/ Philip Molyneaux, MD, PhD, a Professor of Interstitial Lung Disease (ILD) at Imperial College London and the Asthma+Lung UK Chair of Respiratory Research at Royal Brompton Hospital, where is also the Director of the UK National Institute for Health and Care Research (NIHR) Clinical Research Facility, discusses the results of the CORAL study. Neuroblastoma: Beat Childhood Cancer Research Consortium https://checkrare.com/neuroblastoma-beat-childhood-cancer-research-consortium/ Giselle Saulnier Sholler, MD, Division Chief for Pediatric Hematology/Oncology at Penn State University and Founder of the Beat Childhood Cancer Research Consortium, discusses the organization’s work in neuroblastoma. Neuroblastoma: New Approaches to Neuroblastoma Consortium https://checkrare.com/neuroblastoma-new-approaches-to-neuroblastoma-consortium/ Araz Marachelian, MD, Pediatric Oncologist at Children’s Hospital Los Angeles, discusses the New Approaches to Neuroblastoma (NANT) Consortium and its work in neuroblastoma. Watch the DAYBUE® (trofinetide) in Practice Video Series to Hear Expert Insights on the First Treatment for This Rare Disease https://checkrare.com/watch-the-daybue-trofinetide-in-practice-video-series-to-hear-expert-insights-2/ Rett syndrome thought leaders discuss how DAYBUE® (trofinetide), the first and only FDA-approved treatment for Rett syndrome in adults and pediatric patients 2 years of age and older, plays a role in their patients’ treatment plans, while shedding light on their personal experiences with DAYBUE in their practices. Updates in Refractory Chronic Cough From ERS 2025 https://checkrare.com/updates-in-refractory-chronic-cough-from-ers-2025/ Jacky Smith, MB, ChB, FRCP, PhD, Chair of Respiratory Medicine at the University of Manchester, discusses topline results from the phase 2a RIVER trial for patients with refractory chronic cough (RCC). Neuroblastoma: The Children’s Oncology Group https://checkrare.com/neuroblastoma-the-childrens-oncology-group/ Navin Pinto, MD, Professor of Pediatrics at the University of Colorado Anschutz Medical Campus and Colorado Children’s Hospital, discusses the Children’s Oncology Group and their work in neuroblastoma. Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences https://checkrare.com/survey-finds-wide-ranging-impact-of-x-linked-hypophosphatemia-on-patient-experiences/ Al Freedman, PhD, Rare Disease Psychologist and Rare Dad, and Jill H. Simmons, MD, Endocrinologist at Vanderbilt University Medical Center in Nashville, Tennessee discuss the XLH Community Impact Survey and mental health in rare diseases. New Staging Tool Available for Healthcare Providers Treating Patients With CTCL https://checkrare.com/new-staging-tool-available-for-healthcare-providers-treating-patients-with-ctcl/ Pamela Blair Allen, MD, MSc, Hematologist, discusses the new CTCL Staging Tool. Cutaneous T-Cell Lymphoma: Natural History and the Need for Better Diagnostic and Treatment Efficacy https://checkrare.com/cutaneous-t-cell-lymphoma-natural-history-and-the-need-for-better-diagnostic-and-treatment-efficacy/ Henry Wong, MD, PhD, Dermatologist at the San Diego Veterans Hospital and the University of California San Diego (UCSD), discusses cutaneous T-cell lymphoma (CTCL). Chronic Myeloid Leukemia: Diagnosis and Treatment https://checkrare.com/chronic-myeloid-leukemia-diagnosis-and-treatment/ Michael Mauro, MD, Director of the Chronic Myeloid Leukemia Program at Memorial Sloan Kettering Cancer Center, discusses the diagnosis and treatment of chronic myeloid leukemia (CML). Cutaneous T-Cell Lymphoma: Overview, Management, and Quality-of-Life https://checkrare.com/cutaneous-t-cell-lymphoma-overview-management-and-quality-of-life/ Neha Mehta-Shah, MD, Medical Oncologist at Washington University St. Louis, provides an overview of cutaneous T-cell lymphoma (CTCL), discusses management options, and addresses quality-of-life concerns. A New Test for Patient-Reporting of Mastocytosis Control https://checkrare.com/a-new-test-for-patient-reporting-of-mastocytosis-control/ A team of allergists, immunologists, and dermatologists sought to test a new patient-reported outcomes measure for assessing mastocytosis disease control. Their newly developed tool, called the Mastocytosis Control Test (MCT), was generated through interviews with adult patients with nonadvanced indolent systemic mastocytosis.

RARE DISEASE LEARNING CENTERS ++++ +++++++++

RARE DISEASE LEARNING CENTERS Neuroblastoma https://checkrare.com/neuroblastoma/ Neuroblastoma is a rare childhood cancer, but it is the most common extracranial solid tumor in children. It is a neuroendocrine tumor that originates in neuroblasts or neural crest progenitor cells. Rett Syndrome https://checkrare.com/rett-syndrome/ Rett syndrome is a multisystem disorder that primarily affects girls. Only in rare cases are boys affected (who may experience more severe symptoms). Multiple loss-of-function mutations to the MECP2 gene are the cause of Rett syndrome. Cutaneous T-Cell Lymphoma (CTCL) https://checkrare.com/cutaneous-t-cell-lymphoma-2/ Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. Tenosynovial Giant Cell Tumor (TGCT) https://checkrare.com/tenosynovial-giant-cell-tumor-tgct/ Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor involving the joint synovium, bursae, and tendon sheath. These rare tumors are sometimes referred to as giant cell tumor of the tendon sheath (GCT-TS) and/or pigmented villonodular synovitis (PVNS). CME PROGRAMS Case Studies in Diagnosing and Managing FOP Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children’s Practice, focused on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ CREDITS: 1.0 CME | DURATION: 1.0 hours EXPIRES: 10/1/2026 | FEE: $0 ITP Clinical Research Highlights: ISTH 2025 Shruti Chaturvedi, MD, Assistant Professor of Medicine at Johns Hopkins, describes the latest research being presented to better manage individuals with ITP and its clinical relevance. https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/ CREDITS: 0.50 CME | DURATION: 0.50 hours EXPIRES: 9/15/2026 | FEE: $0 Hemophilia Clinical Research Highlights: ISTH 2025 Steven Pipe, MD, Professor of Medicine at the University of Michigan describes the latest research being presented to better manage individuals with hemophilia and its clinical relevance. https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/ CREDITS: 0.75 CME | DURATION: 0.75 hours EXPIRES: 9/15/2026 | FEE: $0 iTTP Clinical Research Highlights: ISTH 2025 Shruti Chaturvedi, MD, Assistant Professor of Medicine at Johns Hopkins, describes the latest research being presented to better manage individuals with iTTP and its clinical relevance. https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/ CREDITS: 0.50 CME | DURATION: 0.50 hours EXPIRES: 9/15/2026 | FEE: $0 Myasthenia Gravis Clinical Research Highlights: AAN 2025 James F. Howard Jr, MD, provides a summary of clinically relevant data presented at AAN 2025 that can enhance the care of patients with myasthenia gravis. https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-aan-2025/ CREDITS: 0.75 CME | DURATION: 0.75 hours EXPIRES: 8/31/2026 | FEE: $0 Skeletal Involvement in Lysosomal Disorders https://checkrare.com/learning/p-skeletal-involvement-in-lysosomal-disorders/ Ozlem Goker-Alpan, MD, Founder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) and Ravi Kamath, MD, PhD, of Fairfax Radiological Consultants & Inova Health System and University of Virginia School of Medicine Fairfax, Virginia, USA discuss best practices to identify and treat bone problems associated with lysosomal disorders. CREDITS: 1.0 CME | DURATION: 1.0 hours EXPIRES: 6/30/2026 | FEE: $0 Fabry Disease Research Highlights Eric Wallace, MD, provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease. https://checkrare.com/learning/p-fabry-disease-research-highlights-2025/ CREDITS: 0.5 CME | DURATION: 0.5 hours EXPIRES: 5/15/2026 | FEE: $0 Transforming Clinical Outcomes with Early Treatment of Lysosomal Disorders Ozlem Goker-Alpan MD, David F. Kronn, MD, Uma Ramaswami FRCPCH, MD, Liz Jalazo, MD, and Lindsay Torrice MSN, CPNP-PC, examine the evidence available to address how to monitor, and possibly treat, children with lysosomal diseases that were diagnosed by newborn screening or soon after birth. https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/ CREDITS: 1.00 CME | DURATION: 1 hour EXPIRES: 4/03/2026 | FEE: $0 Consider Rare: Suspecting and Diagnosing Hereditary Angioedema Jonathan A Bernstein, MD, describes the early symptoms of HAE and its clinical relevance, and discusses best practices to diagnose HAE more efficiently to reduce diagnostic delays. https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/ CREDITS: 0.50 CME | DURATION: 30 minutes EXPIRES: 3/15/2026 | FEE: $0

Which carb threshold best reduces depression (Medscape AI) +... +++++ ++ +++

https://www.medscape.com/ai-search?query=Which%20carb%20threshold%20best%20reduces%20depression&ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 In trials comparing different carbohydrate‐restriction levels, diets providing very low carbohydrate intake (≤10% of total energy) have demonstrated the most pronounced reductions in depressive symptoms, whereas more moderate low‐carbohydrate regimens (11–20% of energy) showed minimal effect. CLINICAL INSIGHTS Is Psilocybin Ready for Clinical Psychiatry? https://www.medscape.com/viewarticle/will-psilocybin-finally-have-its-day-clinical-psychiatry-2025a1000xan?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 Antidepressants Tied to Better Cognition https://www.medscape.com/viewarticle/cognition-improved-some-drugs-depression-2025a1000wbk?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 A Lightbulb Moment in Darkness and Depression https://www.medscape.com/viewarticle/low-intensity-lighting-tied-depression-markers-night-2025a1000xyn?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 New Depression Pathways Go Beyond SSRIs https://www.medscape.com/viewarticle/laughing-gas-depression-data-are-promising-2025a1000xk7?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 Psychotherapy by Text or Video: Which Works Best? https://www.medscape.com/viewarticle/text-vs-video-psychotherapy-which-better-depression-2025a1000wul?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 ALSO OF INTEREST Daily Distress or Mental Illness? A Crisis in Triage https://www.medscape.com/viewarticle/daily-distress-or-mental-illness-crisis-triage-2025a1000yha?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 Can a Cup of Joe Slow Aging in Mental Illness? https://www.medscape.com/viewarticle/coffee-may-slow-biological-aging-severe-mental-illness-2025a1000y2r?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 US DRUG SPOTLIGHT Olanzapine https://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 Olanzapine/Samidorphan https://reference.medscape.com/drug/lybalvi-olanzapine-samidorphan-4000059?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173 Lecanemab https://reference.medscape.com/drug/leqembi-lecanemab-4000310?ecd=mkm_ret_251213_mscpmrk_psych_depression_etid7952173&uac=148436CN&impID=7952173

FDA approves first new kind of drug to target gonorrhea in decades The infection has developed resistance to almost every antibiotic used to treat it

https://www.statnews.com/2025/12/12/fda-approves-zoliflodacin-gonorrhea-pill-marketed-as-nuzolvence/

Everything is changing in dementia diagnosis and treatment That raises new questions for policy, the medical system, patients, and families

https://www.statnews.com/2025/12/13/dementia-revolution-diagnosis-treatment-interview/ By Torie BoschDec. 13, 2025 Editor, First Opinion

Raising the Bar on Breast Cancer Screening and Management Authors: Stamatia V. Destounis, MD, FACR, FSBI, FAIUM; Heather I. Greenwood, MD; Linda Moy, MD; Sarah Eskreis-Winkler, MD, PhD

https://www.medscape.org/viewarticle/raising-bar-breast-cancer-screening-and-management-2025a1000jjj?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251213-OUS-HONC-raising-bar-breast-cancer-screening-and-management-2025a1000jjj-cta

Interpreting JC Virus Test Results in Multiple Sclerosis Management: Are You Up to Speed? Authors: Gavin Giovannoni, MD; Orhan Aktas, MD, PhD; Ruth Dobson, MD, PhD

https://www.medscape.org/viewarticle/interpreting-jc-virus-test-results-multiple-sclerosis-2025a1000qzm?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251213-12071293-ES_LANG-NEUR#transcript-download-es

Navigating Biomarker Conversations: Empowering Patient Understanding in Gastroesophageal Cancer Authors: Sylvie Lorenzen, MD, PhD

https://www.medscape.org/viewarticle/1002840?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251213-OUS-HONC-1002840-cta

How might age-based universal screening change lung cancer detection and mortality rates (Medscape AI) +... ++++++ ++ +++

https://www.medscape.com/ai-search?query=How%20might%20age-based%20universal%20screening%20change%20lung%20cancer%20detection%20and%20mortality%20rates&ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Age-based universal lung cancer screening models project substantial increases in early detection and reductions in mortality compared with current risk-based approaches. Latest Stories Lung Cancer Deaths: How to Potentially Prevent Thousands https://www.medscape.com/viewarticle/expanded-lung-cancer-screening-could-avert-many-more-deaths-2025a1000wxo?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Do ICIs Have Long-Term Survival Benefit? https://www.medscape.com/viewarticle/do-icis-have-long-term-survival-benefit-2025a1000y48?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Unexpected Lung-Brain Cancer Link Revealed https://www.medscape.com/viewarticle/devious-lung-brain-cancer-connection-surprises-researchers-2025a1000wxa?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 ICIs Beyond Progression: Is It Worth It? https://reference.medscape.com/viewarticle/immunotherapy-after-progression-advanced-lung-cancer-nsclc-2025a1000njw?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Neoadjuvant Nivolumab Shows Lasting Gains https://www.medscape.com/viewarticle/neoadjuvant-nivolumab-nsclc-follow-study-confirms-lasting-2025a1000uon?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 SBRT vs Standard RT: Which Offers a QoL Edge in NSCLC? https://www.medscape.com/viewarticle/sbrt-vs-standard-rt-which-offers-qol-edge-nsclc-2025a1000y62?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Case-by-Case When NSCLC Decisions Can’t Wait for NGS https://www.medscape.com/viewarticle/trusting-instinct-when-nsclc-decisions-cant-wait-ngs-2025a1000v64?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Nodal Clues Shift NSCLC Treatment Path https://www.medscape.com/viewarticle/stage-iib-or-iiia-critical-role-nodal-evaluation-nsclc-2025a1000kt9?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 US Drug Spotlight Durvalumab https://reference.medscape.com/drug/imfinzi-durvalumab-1000145?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Cemiplimab https://reference.medscape.com/drug/libtayo-cemiplimab-1000263?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470 Trastuzumab Deruxtecan https://reference.medscape.com/drug/enhertu-trastuzumab-deruxtecan-4000032?ecd=mkm_ret_251214_mscpmrk_onc_lung-cancer_etid7952470&uac=148436CN&impID=7952470

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Free with registration until Dec 15, 2025

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Free with registration until Dec 15, 2025 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00594-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmoasia25&_hsenc=p2ANqtz-9mEwLKB56iQED-WH0i2aVQyssH8uMXU4zILOJnnTljHukqJ_jFfm8Sd1Ztzpmi0K_NzeMlUwPLXYeX08K8iRSIkcTuSw&_hsmi=393141221&utm_content=393141221&utm_source=hs_email

What impact does melatonin have on the sleep cycle (Medscape AI)

https://www.medscape.com/ai-search?query=What%20impact%20does%20melatonin%20have%20on%20the%20sleep%20cycle&ecd=wnl_tp10_daily_251212_MSCPEDIT_etid7949999&uac=148436CN&impID=7949999

Illuminating potential: advancing the science of 2 key pathways in HER2-negative metastatic GC/GEJC/EAC1-4

https://www.medscape.com/infosites/437526.3/isarticle-2?src=0_nl_sm_0&uac=148436CN

Minimizing Toxicity With Regorafenib John L. Marshall, MD · Georgetown University +++ (Videos) Review recommended colorectal cancer guidelines

https://decisionpoint.medscape.com/oncology/viewarticle/922623?src=0_nl_sm_0&uac=148436CN Potential Side Effects of Liver-Directed Therapy https://decisionpoint.medscape.com/oncology/viewarticle/924152?src=0_nl_sm_0&uac=148436CN Benjamin Weinberg, MD, Georgetown University Colonoscopy for CRC Screening: Status Quo in Europe https://decisionpoint.medscape.com/oncology/viewarticle/944858?src=0_nl_sm_0&uac=148436CN Martin D. Berger, MD, Bern University Hospital

Can an oral pill match injectable efficacy for treating LDL (Medscape AI) +... +++ ++++ + +

https://www.medscape.com/ai-search?query=Can%20an%20oral%20pill%20match%20injectable%20efficacy%20for%20treating%20LDL&ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 EMERGING THERAPIES & MANAGEMENT New Gene Therapy a ‘Slam Dunk’ But Raises Flags https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 Time to Overcome PCSK9i Inertia: Experts https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 Off-Label FCS Drug Reduces Lipids, Pancreatitis in Severe HTG https://www.medscape.com/viewarticle/olezarsen-significantly-reduces-triglycerides-pancreatitis-2025a1000vb6?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 SCREENING & EARLY DETECTION Check Your Lp(a): What’s Holding You Back? https://www.medscape.com/viewarticle/i-was-afraid-check-my-lp-now-know-better-2025a1000v92?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 When to Test for Familial Hypercholesterolemia https://www.medscape.com/viewarticle/familial-hypercholesterolemia-key-early-lipid-screening-2025a1000yn1?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 Screening Newborns for High Cholesterol Trait Now Feasible https://www.medscape.com/viewarticle/new-study-demonstrates-feasibility-screening-newborns-2025a1000tz0?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 Keep Peripheral Artery Disease on Your Clinical Radar https://www.medscape.com/viewarticle/keep-peripheral-artery-disease-your-clinical-radar-2025a1000yr4?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 WHAT’S THE DIAGNOSIS? Man With Controlled HTN, Chest Pain, Elevated Lipid Panel https://simulations.medscape.com/edads-156/simulation?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126 US DRUG SPOTLIGHT Inclisiran https://reference.medscape.com/drug/leqvio-inclisiran-4000063?ecd=mkm_ret_251213_mscpmrk_cardio_lipids_etid7952126&uac=148436CN&impID=7952126

RARE DISEASE LEARNING CENTERS & CME PROGRAMS + +++

RARE DISEASE LEARNING CENTERS Learn About WHIM Syndrome https://checkrare.com/learn-about-whim-syndrome/ A rare, congenital primary immunodeficiency disorder associated with neutropenia that typically presents in childhood or adolescence, predominantly caused by pathogenic variants in the CXCR4 chemokine receptor gene. CME PROGRAMS Myasthenia Gravis Clinical Research Highlights: AAN 2025 https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-aan-2025/ James F. Howard Jr, MD, provides a summary of clinically relevant data presented at AAN 2025 that can enhance the care of patients with myasthenia gravis. CREDITS: 0.75 CME | DURATION: 0.75 hours EXPIRES: 8/31/2026 | FEE: $0 Immune Thrombocytopenia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0 Immune Thrombotic Thrombocytopenic Purpura (iTTP) Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0